KR102372288B1 - 단백질 키나아제 억제제로서의 아미노티아졸 화합물 - Google Patents
단백질 키나아제 억제제로서의 아미노티아졸 화합물 Download PDFInfo
- Publication number
- KR102372288B1 KR102372288B1 KR1020197038421A KR20197038421A KR102372288B1 KR 102372288 B1 KR102372288 B1 KR 102372288B1 KR 1020197038421 A KR1020197038421 A KR 1020197038421A KR 20197038421 A KR20197038421 A KR 20197038421A KR 102372288 B1 KR102372288 B1 KR 102372288B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- compound
- alkyl
- atom bonded
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518855P | 2017-06-13 | 2017-06-13 | |
| US62/518,855 | 2017-06-13 | ||
| PCT/US2018/037221 WO2018231910A1 (en) | 2017-06-13 | 2018-06-13 | Aminothiazole compounds as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200014350A KR20200014350A (ko) | 2020-02-10 |
| KR102372288B1 true KR102372288B1 (ko) | 2022-03-08 |
Family
ID=64562741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197038421A Active KR102372288B1 (ko) | 2017-06-13 | 2018-06-13 | 단백질 키나아제 억제제로서의 아미노티아졸 화합물 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10300061B2 (https=) |
| EP (1) | EP3638237B1 (https=) |
| JP (1) | JP6979595B2 (https=) |
| KR (1) | KR102372288B1 (https=) |
| CN (1) | CN110831596B (https=) |
| AU (1) | AU2018284249B2 (https=) |
| CA (1) | CA3064081C (https=) |
| ES (1) | ES2949616T3 (https=) |
| MX (1) | MX393992B (https=) |
| MY (1) | MY201291A (https=) |
| TW (1) | TWI667236B (https=) |
| WO (1) | WO2018231910A1 (https=) |
| ZA (1) | ZA202000107B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102797697B1 (ko) | 2018-05-25 | 2025-04-22 | 에이2에이 파마수티칼스, 잉크. | 신종 항암제 후보로서, 매우 강력한 tacc3 억제제 |
| JP7681018B2 (ja) * | 2019-11-14 | 2025-05-21 | エーツーエー ファーマシューティカルズ インコーポレーテッド | 抗がん剤としてｔａｃｃ３を標的とするイソオキサゾール誘導体 |
| EP4087574A4 (en) * | 2020-03-06 | 2024-01-17 | National Health Research Institutes | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES |
| US11299489B1 (en) | 2020-11-19 | 2022-04-12 | National Health Research Institutes | Thiazole compounds as protein kinase inhibitors |
| KR20240005751A (ko) * | 2021-04-12 | 2024-01-12 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
| EP4499625A4 (en) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | CANCER COMPOSITIONS AND TREATMENT METHODS |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006106437A2 (en) | 2005-04-04 | 2006-10-12 | Ab Science | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors |
| WO2007141571A2 (en) | 2006-06-05 | 2007-12-13 | Merck Sharp & Dohme Limited | Aminothiazole derivatives as inhibitors of mark |
| WO2013014170A1 (en) | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2503715A1 (en) * | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Kinase inhibitors |
| AU2006258101A1 (en) * | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| TW200906825A (en) * | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| US9255072B2 (en) * | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| WO2013143466A1 (zh) * | 2012-03-27 | 2013-10-03 | 广东东阳光药业有限公司 | 作为欧若拉激酶抑制剂的取代嘧啶衍生物 |
| CN106279143A (zh) * | 2015-05-11 | 2017-01-04 | 天津国际生物医药联合研究院 | 噻唑杂环类化合物及其制备方法和应用 |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
-
2018
- 2018-06-11 TW TW107120014A patent/TWI667236B/zh active
- 2018-06-13 ES ES18817380T patent/ES2949616T3/es active Active
- 2018-06-13 CA CA3064081A patent/CA3064081C/en active Active
- 2018-06-13 US US16/007,417 patent/US10300061B2/en active Active
- 2018-06-13 EP EP18817380.1A patent/EP3638237B1/en active Active
- 2018-06-13 MX MX2019014845A patent/MX393992B/es unknown
- 2018-06-13 AU AU2018284249A patent/AU2018284249B2/en active Active
- 2018-06-13 KR KR1020197038421A patent/KR102372288B1/ko active Active
- 2018-06-13 JP JP2019568372A patent/JP6979595B2/ja active Active
- 2018-06-13 MY MYPI2019006791A patent/MY201291A/en unknown
- 2018-06-13 CN CN201880039827.XA patent/CN110831596B/zh active Active
- 2018-06-13 WO PCT/US2018/037221 patent/WO2018231910A1/en not_active Ceased
-
2020
- 2020-01-08 ZA ZA2020/00107A patent/ZA202000107B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006106437A2 (en) | 2005-04-04 | 2006-10-12 | Ab Science | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors |
| WO2007141571A2 (en) | 2006-06-05 | 2007-12-13 | Merck Sharp & Dohme Limited | Aminothiazole derivatives as inhibitors of mark |
| WO2013014170A1 (en) | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
Non-Patent Citations (1)
| Title |
|---|
| Drug Metabolism and Disposition, 2008, 제36권, 제7호, 페이지 1357-1364 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3638237A1 (en) | 2020-04-22 |
| KR20200014350A (ko) | 2020-02-10 |
| WO2018231910A1 (en) | 2018-12-20 |
| EP3638237B1 (en) | 2023-04-19 |
| AU2018284249B2 (en) | 2021-06-24 |
| CA3064081A1 (en) | 2018-12-20 |
| AU2018284249A1 (en) | 2019-12-12 |
| JP6979595B2 (ja) | 2021-12-15 |
| TW201906836A (zh) | 2019-02-16 |
| CN110831596A (zh) | 2020-02-21 |
| CA3064081C (en) | 2023-03-21 |
| ES2949616T3 (es) | 2023-10-02 |
| RU2019137573A3 (https=) | 2021-07-23 |
| TWI667236B (zh) | 2019-08-01 |
| US20180353509A1 (en) | 2018-12-13 |
| NZ759327A (en) | 2021-08-27 |
| MX393992B (es) | 2025-03-24 |
| CN110831596B (zh) | 2025-01-24 |
| BR112019026577A8 (pt) | 2023-04-11 |
| BR112019026577A2 (pt) | 2020-06-23 |
| ZA202000107B (en) | 2020-12-23 |
| MY201291A (en) | 2024-02-15 |
| RU2019137573A (ru) | 2021-05-24 |
| MX2019014845A (es) | 2020-08-06 |
| EP3638237A4 (en) | 2021-01-13 |
| JP2020523348A (ja) | 2020-08-06 |
| US10300061B2 (en) | 2019-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102372288B1 (ko) | 단백질 키나아제 억제제로서의 아미노티아졸 화합물 | |
| CN110772638B (zh) | Alk抑制剂与egfr抑制剂在制备治疗癌症的药物中的用途 | |
| CN109369671B (zh) | 作为Raf激酶和/或Raf激酶二聚体抑制剂的稠合三环脲类化合物 | |
| EP2498607B1 (en) | Kinase inhibitors | |
| BR112012010085B1 (pt) | composto, quantidade terapeuticamente eficaz de um composto, formulação farmacêutica | |
| WO2020210481A1 (en) | Heterocyclic compounds as kinase inhibitors for therapeutic uses | |
| EP3411035A1 (en) | Aminothiazole compounds and use thereof | |
| AU2015290007B2 (en) | Fused quinoline compunds as pi3k, mTor inhibitors | |
| KR20210066839A (ko) | Fgfr4 저해제 및 그것의 용도 | |
| WO2018187294A1 (en) | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof | |
| KR102325899B1 (ko) | 퀴나졸린 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 | |
| MX2014009524A (es) | Derivados de triazolopiridina como un inhibidor de quinasa tirosina. | |
| CN115707704B (zh) | 氘代稠合三环类化合物及其组合物和用途 | |
| RU2772645C2 (ru) | Аминотиазольные соединения в качестве ингибиторов протеинкиназ | |
| TWI750905B (zh) | 噻唑化合物作為蛋白質激酶抑制劑 | |
| US11299489B1 (en) | Thiazole compounds as protein kinase inhibitors | |
| HK40017909A (en) | Aminothiazole compounds as protein kinase inhibitors | |
| NZ759327B2 (en) | Aminothiazole compounds as protein kinase inhibitors | |
| HK40017909B (zh) | 作为蛋白激酶抑制剂的氨基噻唑化合物 | |
| BR112019026577B1 (pt) | Compostos aminotiazol, composição farmacêutica e uso como inibidores de proteína quinase e no tratamento de câncer | |
| KR20250041906A (ko) | Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물 | |
| KR20240156074A (ko) | Hpk1 및 mlk3 저해제 및 이를 함유하는 항암용 조성물 | |
| HK40021582A (en) | Use of alk inhibitor and egfr inhibitor in preparation of a medicine for treating cancer | |
| HK40021582B (en) | Use of alk inhibitor and egfr inhibitor in preparation of a medicine for treating cancer | |
| HK1263053A1 (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20191226 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210527 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20210527 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20211008 Patent event code: PE09021S01D |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20220207 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220218 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220303 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20220304 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20250305 Start annual number: 4 End annual number: 4 |